Compare Bristol-Myers Squibb Co (BMY) vs Roundhill NVDA WeeklyPay ETF (NVDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Roundhill NVDA WeeklyPay ETF — how do they compare? Bristol-Myers Squibb Co trades at $63.65 (market cap $129.94B), while Roundhill NVDA WeeklyPay ETF trades at $38.32. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Roundhill NVDA WeeklyPay ETF pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, Roundhill NVDA WeeklyPay ETF nearer its low. Which is the better fit depends on your goals.
| BMY | NVDW | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $65.89 | $52.59 |
52-Week Low | $42.60 | $31.88 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
NVDW trades at $38.58, up 3.35% today with a bullish technical signal supported by moving averages. The stock shows strong momentum with key indicators suggesting mild overbought conditions. Recent dividend activity indicates consistent shareholder returns, though financial ratios remain undisclosed pending updated filings.
Outlook remains positive given technical strength and dividend consistency, but limited fundamental data requires caution. Key risks include dependency on underlying NVDA performance and payout volatility. Investors should await comprehensive financial disclosures for full valuation assessment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Roundhill NVDA WeeklyPay ETF
NVDW is an actively managed ETF that seeks to provide weekly distributions and returns equal to 1.2 times (120%) the calendar week performance of Nvidia (NVDA) common shares. It combines modest leverage with a high-frequency payout schedule, designed for investors who want amplified exposure to Nvidia alongside a consistent weekly income stream.
Read more on NVDW →
